Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.791
Abstract: We report pharmacokinetics, pharmacodynamics, and safety of a novel anti‐CD28 domain antibody antagonist (lulizumab pegol) in healthy subjects following single‐ or multiple‐dose administration. A minimal anticipated biological effect level approach was used to select a… read more here.
Keywords: antibody antagonist; anti cd28; novel anti; domain antibody ... See more keywords